Evaluation of Safety and Efficacy of Three Flavors of Supportan® Drink in Cancer Patients in Taiwan

Exclusion Criteria

• •1. Patient with documented diagnosis of liver, kidney or heart disease in the hospital's electronic medical record (EMR); severity of disease evaluated by Investigator as not being suitable to participate in this study;
• •2. Current alcohol or substance abuse as assessed by Investigator;
• •3. Patient had a stroke in the past year and is after Investigator assessment judged as not yet clinically stable at the time of screening;
• •4. Patients who are diagnosed with mental illness or depression assessed by the Investigator as too severe for being suitable to participate in this study;
• •5. Pregnant or breastfeeding woman;
• •6. Allergic to any ingredient of the investigational products;
• •7. Patients receiving or having received standard (not disease specific) oral nutritional supplements (ONS), standard enteral formula/tube feeding or standard parenteral cancerspecific nutrition supplements in the last 3 days;
• •8. Patients receiving or having received ONS, enteral formula/tube feeding or parenteral nutrition with high fish oil or high EPA/DHA content (above 1 g/day) in the last 28 days;
• •9. Current use of medication, food supplements or ONS containing more than 500 mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)/day or fish oil capsules/supplements containing more than 500 mg EPA and DHA/day at screening;
• •10. Transfusion of blood products within 1 week before screening;
• •11. Surgery scheduled during the trial;
• •12. Participation in other clinical trials using investigational drugs within 14 days before the start of the trial or during the trial.